Is Teladoc Health (TDOC) Cheap Following Its New AI Tools?
Teladoc Health (TDOC) just rolled out two AI tools inside its Solo platform, SoloVitals and SoloScribe, aimed at contactless vital sign tracking and streamlined clinical note taking for hospital and health system clients.
Despite Teladoc Health unveiling AI tools aimed at making virtual visits smoother for hospitals, the 30-day share price return is down 10% and the 90-day move has fallen 41.24%. The 5-year total shareholder return has declined 95.88%, pointing to longer term momentum that remains weak.
Look beyond Teladoc Health and compare it with other AI-focused healthcare plays by checking the hand-picked 33 healthcare AI stocks that could be shaping the next wave of virtual care.
Teladoc Health trades near US$5.67 after a long slide and fresh AI product news. Does it make more sense to step in now, or to wait for a cheaper entry until the numbers justify any move?
Most Popular Narrative: 62% Undervalued
Teladoc Health closed at $5.67 while the most followed narrative on the stock pegs fair value closer to $15. That gap frames the current AI product news against a thesis that sees the virtual care group as materially mispriced.
Despite the market narrative of a failing pandemic stock, Teladoc’s underlying financial engine tells a radically different story.
Unlike cash-burning biotech or tech peers, Teladoc generated $166.9M in FCF in 2025 and is guided to deliver $130M to $170M in FCF for FY2026.
See why 3 investors see Teladoc Health as 62% undervalued.
Result: Fair Value of $15 (UNDERVALUED)
Still, that cash flow story can crack quickly if the BetterHelp insurance shift drags on margins or if telehealth rivals keep squeezing Teladoc Health on pricing.
Find out about the key risks to this Teladoc Health narrative.
Next Steps
If Teladoc Health feels like a turnaround story in motion, treat the current narrative as a prompt to move fast and check the underlying data yourself. Balance the concerns against the potential upside by reviewing the 3 key rewards and 2 important warning signs.
Looking for more Teladoc Health investment ideas?
Do not stop with Teladoc Health. Use the Simply Wall St screener to uncover fresh ideas that match your risk level and return goals before the crowd moves on.
- Target missed opportunities by scanning a curated 20 high quality undiscovered gems that many investors have not fully priced in yet.
- Strengthen portfolio resilience by focusing on a list of solid balance sheet and fundamentals (25 results) that can better handle funding pressures and economic shocks.
- Reduce downside surprises by filtering for 32 resilient stocks with low risk scores with metrics aimed at steadier fundamentals and lower overall business risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com